(Q38131100)

29 August 2017

title

Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment (English)

1 reference

systemic lupus erythematosus

29 August 2017

main subject

0 references

1 reference

3

David Isenberg

1 reference

29 August 2017

Grainne Murphy

1

1 reference

29 August 2017

Larissa Lisnevskaia

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

23 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

382

1 reference

29 August 2017

issue

9894

1 reference

29 August 2017

page(s)

809-818

1 reference

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Pathogenesis of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Rituximab and lupus interstitial lung disease: friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Colitis associated with active systemic lupus erythematosus successfully treated with rituximab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Rituximab in the treatment of bullous systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Six refractory lupus patients treated with rituximab: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Off-label use of rituximab in systemic lupus erythematosus: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Treatment of systemic lupus erythematosus with epratuzumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Belimumab: in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Abetimus sodium: a medication for the prevention of lupus nephritis flares

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

T cell receptor repertoire of T cells in the kidneys of patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Abatacept in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Therapeutic effect of tocilizumab on two patients with polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Autoimmune Diseases Induced by TNF-Targeted Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

A randomized, pilot trial of etanercept in dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Serum interferon levels in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Autologous stem cell transplantation for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960889-2

7 January 2021

10.1016/S0140-6736(13)60889-2

Identifiers

DOI

1 reference

29 August 2017

1 reference